AllPennyStocks.com QURE Stock Fades After AMT-130 filing — But William Blair Sees 58% Upside
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

QURE Stock Fades After AMT-130 filing — But William Blair Sees 58% Upside

uniQure announced it had submitted a Biologics License Application to the FDA seeking accelerated approval of ifezuntirgene inilparvovec, or AMT-130, for Huntington’s disease.

Other Penny Stock Movers

This Critical Minerals Explorer Just Found Where to Look Next
This Cannabis Microcap Just Bought Its Way Into Two of Europe's Biggest Markets
BC Copper-Gold Explorer Surges 40% on Maiden Drill Visuals
Most Popular
{{ index + 1 }}


Back to Top